Search

Author/Creator Paul, Robert

5. ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease. (22nd May 2018)

Authors:
Cummings, Jeffrey L.; Cohen, Sharon; van Dyck, Christopher H.; Brody, Mark; Curtis, Craig; Cho, William; Ward, Michael; Friesenhahn, Michel; Rabe, Christina; Brunstein, Flavia; Quartino, Angelica; Honigberg, Lee A.; Fuji, Reina N.; Clayton, David; Mortensen, Deborah; Ho, Carole; Paul, Robert
Journal:
Neurology
Issue:
Volume 90:Number 21(2018)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. AL001 restores CSF PGRN levels and normalizes disease‐associated biomarkers in individuals with frontotemporal dementia due to heterozygous mutations in the progranulin gene: Human: Putative therapeutic results for Alzheimer's and related dementias. (7th December 2020)

Authors:
Haynes, Beth Ann; Rhinn, Herve; Yeh, Felix L; Long, Hua; Ward, Michael; Hagey, Mackenzie; Siddiqui, Omer; Paul, Robert
Journal:
Alzheimer's & dementia
Issue:
Volume 16(2020)Supplement 9
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗